Now in Part 2 of our April feature about clinical trial regulations, we look at the implications for researchers and see some success from recent regulatory changes governing clinical trials. The recent changes in clinical trial regulations have several implications for researchers: Increased Transparency: The push for increased transparency means that researchers are now required to register their trials and report their results in a timely manner. This can increase the workload for researchers but also helps to prevent selective reporting and publication bias. Data Protection: The ena ..read more

For this month, we take a look at the regulations surrounding clinical trials and their impact. In part 1 of 2, we ask: “Why are Clinical Trial Regulations so Stringent?” Clinical trials are the backbone of medical advancements. They provide the necessary data to determine whether new treatments are safe and effective. However, these trials are governed by stringent regulations. But why is this so?   Protecting Participants The primary reason for stringent regulations is to protect the rights, safety, and well-being of trial participants. These regulations ensure that the benefits of part ..read more

Dr. D. Ross Camidge, Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), and Dr. David Gerber, one of the founding members of ATOMIC, and Associate Professor of Internal Medicine within the Hematology/Oncology Division at UT Southwestern Medical Center, discuss how a liberal arts education can serve as a foundation for a successful medical career, the benefits of face-to-face, personalized patient connections versus digital interactions, and the value in keeping a humble and service-focused approach when providing patient care. Dr. Camidge is a distinguished l ..read more

Dr. Thomas Flaig of the University of Colorado and Director of the Academic Urology Research Investigators Consortium (AURIC) discusses recent developments in bladder cancer treatment, including immune checkpoint inhibitors. Watch the Video at TargetedOnc.com   About Thomas Flaig, MD Thomas Flaig, MD, was appointed vice chancellor for research for the CU Denver and CU Anschutz Medical Campus in March of 2020. A medical oncologist, Dr. Flaig has been part of CU since 2003, when he arrived as an oncology fellow. In 2016, he became the inaugural chief clinical research officer of UCHealth an ..read more

Dr. Thomas Flaig of the University of Colorado and Director of the Academic Urology Research Investigators Consortium (AURIC) discusses how antibody-drug conjugates are used in the treatment of advanced urothelial cancer. Watch the Video at JNCCN360.org, part of the National Comprehensive Cancer Network   About Thomas Flaig, MD Thomas Flaig, MD, was appointed vice chancellor for research for the CU Denver and CU Anschutz Medical Campus in March of 2020. A medical oncologist, Dr. Flaig has been part of CU since 2003, when he arrived as an oncology fellow. In 2016, he became the inaugural c ..read more

Previously we posted on the importance of clinical trials – this entry addresses the other side of the question. Participating in a clinical trial can offer both advantages and disadvantages for patients. These pros and cons should be carefully considered by individuals when deciding whether to enroll in a clinical trial. It’s important to note that the specific benefits and drawbacks may vary depending on the trial’s nature, phase, and the patient’s unique circumstances. Here are some of the key pros and cons of patient participation in clinical trials: Pros: Access to Novel Treatments: Clin ..read more

We start the new year with a look at the importance of clinical trials… Introduction: Clinical research studies play a pivotal role in shaping the future of medicine and healthcare. These studies are designed to investigate the safety and effectiveness of new treatments, medications, and medical devices, ultimately aiming to improve patient care and outcomes. As a critical aspect of medical progress, clinical research brings hope to patients and offers them access to cutting-edge therapies that have the potential to change lives. In this blog, we will explore how clinical research studies bene ..read more

Recognized by: Tejas Patil, MD, University of Colorado D. Ross Camidge, MD, PhD Dr. Camidge is, in many ways, a doctor of “firsts.” His discoveries in the clinic and insights into lung cancer have been the spark for thousands of patients and hundreds of other physicians, scientists, and pharma companies to then explore in their own lives and work. Every year since 2017, Dr. Camidge has been internationally recognized as a Clarivate Analytics Highly Cited Researcher (top 1% of all authors in clinical medicine) and at the World Expert level for Lung Cancer (top 0.0043%). He has personally advise ..read more

Dr. Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab on patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin. The objective was to describe the impact on the patients’ quality of life (QoL), functioning, and symptoms. The combination of EV and pembrolizumab demonstrated an objective response rate of 64.5%, whereas EV monotherapy had an objective response rate of 45.2%. The quality o ..read more

Camidge received the organization’s Daniel C. Ihde Lectureship Award for Medical Oncology University of Colorado Cancer Center member Ross Camidge, MD, PhD, has seen huge advances in lung cancer treatment during his years in the field. As he put it in a recent address, “not that long ago, and still for many with lung cancer, their new diagnosis feels like looking down the barrel of a gun. Yet at the same time we can now also fill a room with select long-term survivors of the disease.” Dr. Camidge, the Joyce Zeff Chair in Lung Cancer Research in the CU School of Medicine, delivered that speech ..read more